What Is New in the Anti–Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Cellular and Infection Microbiology"
DOI: 10.3389/fcimb.2022.909731
Abstract: The spread of antibiotic-resistant bacteria poses a substantial threat to morbidity and mortality worldwide. Carbapenem-resistant Pseudomonas aeruginosa (CRPA) are considered “critical-priority” bacteria by the World Health Organization (WHO) since 2017 taking into account criteria such… read more here.
Keywords: development; since 2017; anti; clinical development ... See more keywords
Antimicrobial innovation: a current update and perspective on the antibiotic drug development pipeline.
Sign Up to like & getrecommendations! Published in 2020 at "Future medicinal chemistry"
DOI: 10.4155/fmc-2020-0225
Abstract: As bacteria continue to develop resistance to our existing treatment options, antibiotic innovation remains overlooked. If current trends continue, then we could face the stark reality of a postantibiotic era, whereby routine bacterial infections could… read more here.
Keywords: drug development; development pipeline; antibiotic drug;